TRPC6 G757D Loss-of-Function Mutation Associates with FSGS

J Am Soc Nephrol. 2016 Sep;27(9):2771-83. doi: 10.1681/ASN.2015030318.

Marc Riehle ¹, Anja K Büscher ², Björn-Oliver Gohlke ³, Mario Kaßmann ⁴, Maria Kolatsi-Joannou ⁵, Jan H Bräsen ⁶, Mato Nagel ⁷, Jan U Becker ⁸, Paul Winyard ⁵, Peter F Hoyer ², Robert Preissner ³, Dietmar Krautwurst ⁹, Maik Gollasch ⁴, Stefanie Weber ¹⁰, Christian Harteneck ¹¹

Affiliations

1 Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls University Hospitals and Clinics and Interfaculty Center of Pharmacogenomics and Drug Research, University of Tübingen, Tübingen, Germany;
2 Pediatric Nephrology, Pediatrics II, University of Duisburg-Essen, Essen, Germany;
3 German Cancer Consortium, Heidelberg, Germany; Charité University Medicine Berlin, Structural Bioinformatics Group, Institute of Physiology and Experimental Clinical Research Center, Berlin, Germany;
4 Nephrology/Intensive Care, Experimental and Clinical Research Center and Max Delbrück Center for Molecular Medicine, Charité University Medicine Berlin, Berlin, Germany;
5 Nephro-Urology Unit, University College London Institute of Child Health, London, United Kingdom;
6 Institute of Pathology, University Hospital of Hannover, Hannover, Germany;
7 Center of Nephrology and Metabolism, Weisswasser, Germany;
8 Institute of Pathology, University Hospital of Cologne, Cologne, Germany; and.
9 Deutsche Forschungsanstalt für Lebensmittelchemie, Molekulare Zellphysiologie und Chemorezeption, Freising, Germany.
10 Pediatric Nephrology, Pediatrics II, University of Duisburg-Essen, Essen, Germany; stefanie.weber@uk-essen.de christian.harteneck@uni-tuebingen.de.
11 Department of Pharmacology and Experimental Therapy, Institute of Experimental and Clinical Pharmacology and Toxicology, Eberhard Karls University Hospitals and Clinics and Interfaculty Center of Pharmacogenomics and Drug Research, University of Tübingen, Tübingen, Germany; stefanie.weber@uk-essen.de christian.harteneck@uni-tuebingen.de.

PMID: 26892346 DOI: 10.1681/ASN.2015030318

Abstract

FSGS is a CKD with heavy proteinuria that eventually progresses to ESRD. Hereditary forms of FSGS have been linked to mutations in the transient receptor potential cation channel, subfamily C, member 6 (TRPC6) gene encoding a nonselective cation channel. Most of these TRPC6 mutations cause a gain-of-function phenotype, leading to calcium-triggered podocyte cell death, but the underlying molecular mechanisms are unclear. We studied the molecular effect of disease-related mutations using tridimensional in silico modeling of tetrameric TRPC6. Our results indicated that G757 is localized in a domain forming a TRPC6-TRPC6 interface and predicted that the amino acid exchange G757D causes local steric hindrance and disruption of the channel complex. Notably, functional characterization of model interface domain mutants suggested a loss-of-function phenotype. We then characterized 19 human FSGS-related TRPC6 mutations, the majority of which caused gain-of-function mutations. However, five mutations (N125S, L395A, G757D, L780P, and R895L) caused a loss-of-function phenotype. Coexpression of wild-type TRPC6 and TRPC6 G757D, mimicking heterozygosity observed in patients, revealed a dominant negative effect of TRPC6 G757D. Our comprehensive analysis of human disease-causing TRPC6 mutations reveals loss of TRPC6 function as an additional concept of hereditary FSGS and provides molecular insights into the mechanism responsible for the loss-of-function phenotype of TRPC6 G757D in humans.

Keywords

calcium; glomerular disease; glomerulosclerosis; ion channel; kidney disease.

Name
Email *

	Sorry, but the email address you supplied was invalid.